Novartis takes 85% stake in Chinese vaccine firm

Published: 4-Nov-2009
Media Pharmaceutical

Swiss drugmaker Novartis is to acquire an 85% stake in Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical for US$125m to expand its presence in this fast-growing market.


Swiss drugmaker Novartis is to acquire an 85% stake in Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical for US$125m to expand its presence in this fast-growing market.

Tianyuan is a privately owned vaccine company offering a range of marketed vaccine products in China and r&d projects focused on various preventable viral and bacterial diseases. Tianyuan more than doubled its net sales to approximately US$25m in 2008 compared with 2006.

"Our future activities with Tianyuan are an important step in our strategy to enhance the prevention of diseases in China with high-quality products," said Daniel Vasella, chief executive of Novartis.

Ding Xiaohang, founder, chairman and ceo of Tianyuan will continue to lead this business while holding a minority stake.

The transaction is subject to government and regulatory approvals in China.

Earlier this week Novartis said it would invest US$1bn over the next five years to build the largest comprehensive r&d centre in China by significantly expanding the Novartis Institute of BioMedical Research (CNIBR) in Shanghai and investing US$250m in a new global technical centre in Changshu.

  • Companies:
  • Novartis
See more

You may also like

Regulatory

Novartis obtains FDA approval for CML drug, Scemblix

Read more
The TKI's approval is an important step forward for oncology patients with newly diagnosed chronic myeloid leukaemia, and was based on the results of the Phase III ASC4FIRST trial

Trending Articles

  1. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  2. Dual-chamber packaging systems as a simplification factor in the supply chain Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
  3. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms
  4. Indian government bans three medicines owing to health risks Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
  5. Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Regulatory

Novartis obtains FDA approval for CML drug, Scemblix

The TKI's approval is an important step forward for oncology patients with newly diagnosed chronic myeloid leukaemia, and was based on the results of the Phase III ASC4FIRST trial
Pharmaceutical

Pharma giants Roche and Novartis top worldwide reputation poll

The report examined the reputations of the 34 biggest pharmaceutical companies globally, including GSK, Novartis, Pfizer, Moderna and Johnson & Johnson
Manufacturing

Novartis opens facility for innovative cell and gene therapies in Switzerland

New building in Stein also hosts the production of difficult-to-manufacture solid dosage forms
Finance

Lonza to buy sterile drug product fill-finish facility from Novartis

Swiss CDMO bids to keep management and operations teams and manufacture for Novartis at the site in Stein
Regulatory

Novartis starts voluntary recall after peanut contamination scare

Three lots of Promacta 12.5 mg for oral suspension to the consumer level have been recalled due to cross-contamination risk
Research & Development

Blackstone and Novartis: Joint venture targets cardiovascular disease

Anthos Therapeutics enters the market with US$250 million backing from Blackstone and an anti-thrombotic licensed from Novartis
Ingredients

Therapeutics: anticancer agent: alpelisib

Phosphoinositide 3-kinase enzymes are a group of intracellular signal transducers that phosphorylate the 3-hydroxyl group of phosphatidylinositol
Subscribe now